Live
- Must-Watch OTT Originals in 2024: The Year’s Best Shows and Movies
- 40 Indian startups secure over $787 mn in a week
- India now formidable force on chess board
- Raghavendra Mutt pontiff visits Tirumala
- Whistleblower of OpenAI found dead in US apartment
- Trump’s US-first policy & India’s strategic latitude
- Chandrababu pays tribute to Potti Sriramulu and Sardar Vallabhbhai Patel
- India may miss TB elimination target
- Revolutionizing Women’s Health: The Era of AI
- Govt bill explains plan for ONOE
Ranbaxy drugs adulteration charges: SC seeks health ministry's reply
M L Sharma had contended that \" Ranbaxy was fined USD 500 million by the US Food and Drug Administration (USFDA) for making and selling adulterated drugs\" and sought a CBI probe against the drug maker.
New Delhi: The Supreme Court on Monday sought Health Ministry's response on allegations of adulteration of drugs manufactured by Ranbaxy Laboratories.
A Public Interest Litigation (PIL) filed by advocate M L Sharma, has sought the shutting down the three plants, located in Himachal Pradesh, Madhya Pradesh and New Delhi on charges of adulteration.
The apex court has asked the ministry to probe the matter. The Supreme Court has posted the matter for hearing after two weeks.
The Supreme Court had last month directed Ranbaxy to respond to a PIL seeking a probe by the Central Bureau of Investigation (CBI) for allegedly supplying adulterated drugs in the country. The apex court had also asked the government to reply to the plea that sought the court's direction for cancellation of the drug major's licence.
M L Sharma had contended that " Ranbaxy was fined USD 500 million by the US Food and Drug Administration (USFDA) for making and selling adulterated drugs" and sought a CBI probe against the drug maker.
